CORTINOVIS DIEGO LUIGI

Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Dettaglio

Cortellini, A., Brunetti, L., Di Fazio, G., Garbo, E., Pinato, D., Naidoo, J., et al. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 13(2) [10.1136/jitc-2024-010674]. Dettaglio

De Marinis, F., Ardizzoni, A., Attili, I., Bonanno, L., Bria, E., Cortinovis, D., et al. (2025). Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting. CURRENT ONCOLOGY, 32(2) [10.3390/curroncol32020110]. Dettaglio

Clementi, T., Colonese, F., Canova, S., Abbate, M., Sala, L., Petrella, F., et al. (2025). Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences. CURRENT ONCOLOGY, 32(7) [10.3390/curroncol32070397]. Dettaglio

Cortellini, A., Santo, V., Brunetti, L., Garbo, E., Pinato, D., La Cava, G., et al. (2025). Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 13(9) [10.1136/jitc-2025-012423]. Dettaglio